Sugi Predict

Sugi Predict / Compounds / SCHEMBL261608

SCHEMBL261608

SCHEMBL261608

N=C(N)NCCCC(=O)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ PLA2G4A P47712 1/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ SLC13A3 Q8WWT9 1/20 0.36
▸ EGLN1 Q9GZT9 1/20 0.36
▸ OR51E2 Q9H255 1/20 0.36
▸ PLA2G2A P14555 2/20 0.33
▸ ALB P02768 1/20 0.33
▸ PRMT1 Q99873 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ F2 P00734 1/20 0.32
▸ PLG P00747 1/20 0.32
▸ PRSS1 P07477 1/20 0.32
▸ PRSS2 P07478 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30194456 0.94 ALOX15 (0.44) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL33717 0.83 PRMT1 (0.50) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL29305410 0.83 PLA2G4A (0.39) ALOX15PLA2G4AMAPK1SLC13A3EGLN1
SCHEMBL31372702 0.83 PRMT1 (0.50) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
Tiformin SCHEMBL828055 0.82 ALOX15 (0.47) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL24919988 0.82 CES1 (0.45) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
Hydrochloric Acid SCHEMBL8613561 0.81 PRMT1 (0.48) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
Tiformin SCHEMBL9772228 0.80 ALOX15 (0.46) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
Bicarbonate SCHEMBL9192764 0.80 ALOX15 (0.48) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL9809324 0.79 ALOX15 (0.42) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3899045-B1 METHODS FOR IDENTIFYING A COMPANION ANIMAL SUSCEPTIBLE TO TREATMENT THAT REDUCES THE RISK OF STONE FORMATION AND USE OF COMPOSITIONS FOR REDUCING SUCH RISK HILLS PET NUTRITION INC (US) 2025-09-10 — — EP claimed
US-12292445-B2 Methods of selecting subjects for treatment with metabolomic modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-05-06 — — US claimed
US-20250043352-A1 Methods for Identifying a Companion Animal at Risk of Calcium Oxalate Stone Formation and Treatments and Compositions for Reducing the Risk HILL'S PET NUTRITION, INC. (US) 2025-02-06 — — US claimed
WO-2024254556-A9 BACTERIAL COMPOSITIONS FOR METABOLIZING UREMIC TOXINS ATOSSA THERAPEUTICS, INC. (US) 2025-01-30 — — WO claimed
WO-2024254556-A1 BACTERIAL COMPOSITIONS FOR METABOLIZING UREMIC TOXINS ATOSSA THERAPEUTICS, INC. (US) 2024-12-12 — — WO claimed
EP-4022089-B1 METHODS FOR IDENTIFYING A COMPANION ANIMAL AT RISK OF CALCIUM OXALATE STONE FORMATION AND MEDICAL USES FOR REDUCING THE RISK HILLS PET NUTRITION INC (US) 2024-08-21 — — EP claimed
US-20240009284-A1 METHOD AND COMPOSITION FOR TREATING ARGINASE 1 DEFICIENCY AERASE, INC. 2024-01-11 — — US claimed
US-20230410977-A1 METHODS AND MATERIALS FOR ASSESSING RADIATION EXPOSURE NUTECH VENTURES 2023-12-21 — — US claimed
US-20230405091-A1 METHODS OF MODULATING GASTROINTESTINAL METABOLITES DSM IP ASSETS B.V. (NL) 2023-12-21 — — US claimed
EP-4228424-A1 METHODS OF MODULATING GASTROINTESTINAL METABOLITES DSM IP Assets B.V. (NL) 2023-08-23 — — EP claimed
US-20130011364-A1 MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) 2013-01-10 — — US claimed
JP-2011529088-A — — 2011-12-01 — — JP claimed
WO-2011119637-A1 PREDICTING HUMAN DEVELOPMENTAL TOXICITY OF PHARMACEUTICALS USING HUMAN STEM-LIKE CELLS AND METABOLOMICS STEMINA BIOMARKER DISCOVERY, INC. (US) 2011-09-29 — — WO claimed
WO-2011113607-A1 MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) 2011-09-22 — — WO claimed
US-20110165261-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC (US) 2011-07-07 — — US claimed
EP-2326171-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE Georgia State University Research Foundation, Inc. (US) 2011-06-01 — — EP claimed
US-20100116691-A1 BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF UNIVERSITY OF CONNECTICUT (US) 2010-05-13 — — US claimed
WO-2010011998-A9 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2010-03-18 — — WO claimed
WO-2010011998-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2010-01-28 — — WO claimed
US-6287620-B1 Flavor enhancing methods FIRMENICH SA (CH) 2001-09-11 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165261-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE MPO, CUTA, LPO ALOX15 363/4885MEN1 4710/4885CYP1A2 3822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.